153 related articles for article (PubMed ID: 33261292)
1. Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.
Perisano C; Vitiello R; Sgambato A; Greco T; Cianni L; Ragonesi G; Malara T; Maccauro G; Martini M
J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 3):289-294. Congress of the Italian Orthopaedic Research Society. PubMed ID: 33261292
[TBL] [Abstract][Full Text] [Related]
2. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Torabi A; Amaya CN; Wians FH; Bryan BA
Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
[TBL] [Abstract][Full Text] [Related]
3. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.
Kim JR; Moon YJ; Kwon KS; Bae JS; Wagle S; Kim KM; Park HS; Lee H; Moon WS; Chung MJ; Kang MJ; Jang KY
PLoS One; 2013; 8(12):e82870. PubMed ID: 24349382
[TBL] [Abstract][Full Text] [Related]
4. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Italiano A; Bellera C; D'Angelo S
J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
[TBL] [Abstract][Full Text] [Related]
5. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
[TBL] [Abstract][Full Text] [Related]
6. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
7. PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas.
Siozopoulou V; Smits E; Zwaenepoel K; Liu J; Pouliakis A; Pauwels PA; Marcq E
Immunotherapy; 2023 Oct; 15(15):1257-1273. PubMed ID: 37661910
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
Vargas AC; Maclean FM; Sioson L; Tran D; Bonar F; Mahar A; Cheah AL; Russell P; Grimison P; Richardson L; Gill AJ
PLoS One; 2020; 15(4):e0222551. PubMed ID: 32294103
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
11. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Paydas S; Bagir EK; Deveci MA; Gonlusen G
Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
[TBL] [Abstract][Full Text] [Related]
13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
[TBL] [Abstract][Full Text] [Related]
16. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).
Berghoff AS; Ricken G; Widhalm G; Rajky O; Hainfellner JA; Birner P; Raderer M; Preusser M
Clin Neuropathol; 2014; 33(1):42-9. PubMed ID: 24359606
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D
Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333
[TBL] [Abstract][Full Text] [Related]
19. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
20. Status of programmed death-ligand 1 expression in sarcomas.
Park HK; Kim M; Sung M; Lee SE; Kim YJ; Choi YL
J Transl Med; 2018 Nov; 16(1):303. PubMed ID: 30400799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]